20.9% Average Loss With Tirzepatide at 72 Weeks
SURMOUNT-1 evaluated three once-weekly tirzepatide doses with lifestyle intervention in adults without diabetes. The headline result comes from the 15 mg arm at week 72 and is an average outcome under the trial’s defined conditions.
Mean body-weight change was −20.9% with tirzepatide 15 mg and −3.1% with placebo.
At the 15 mg dose, 56.7% of participants reached at least 20% weight reduction versus 3.1% with placebo. Gastrointestinal adverse events were common, generally mild to moderate, and occurred mainly during dose escalation.
Turn the study result into a better program comparison
A positive trial result is a reason to investigate your options—not a substitute for comparing them. Review these GLP-1 programs for the plans they offer, clinician model, price disclosures, and enrollment conditions before taking the next step. Inclusion reflects category-matched affiliate offers, not a study relationship.
From $49 – $129/mo · Editorial score 4.7/5
Featured value terms: semaglutide $49/mo or tirzepatide $89/mo with 12-month prepayment; $99/$129 month to month.
We may earn a commission through provider links. Matching affiliate offers and editorial priorities affect inclusion and suggested order in commercial guides. Scores are not clinical endorsements. Disclosure · Methodology
Study details
- Population
- 2,539 adults with obesity or overweight plus a weight-related complication, excluding diabetes
- Follow-up
- 72 weeks
- Treatment comparison
- Once-weekly tirzepatide 5 mg, 10 mg, or 15 mg compared with placebo, alongside lifestyle intervention
- Study design
- Phase 3, double-blind, randomized, placebo-controlled trial
A study result is not a personal treatment plan
The result does not establish what a specific telehealth provider can prescribe, how a person will tolerate dose escalation, or what insurance will cover. Those are individual clinical and coverage questions that require a licensed prescriber and a review of current program terms.
Compare tirzepatide and semaglutide programsWhat this result does not show
- The 20.9% figure is the 15 mg tirzepatide dose-arm result; lower-dose results were different.
- The trial enrolled adults without diabetes who met its BMI and weight-related-condition criteria.
- The study does not compare telehealth providers, medication sourcing, coaching, access, affordability, or individual outcomes.
- The study was funded by Eli Lilly; the peer-reviewed paper and disclosures are linked at the end of this article.
Related Studies
Explore other peer-reviewed results in Evidence Watch before comparing programs or discussing options with a clinician.
Primary peer-reviewed source
Read the full paper, methodology, conflict-of-interest disclosures, and supplementary materials before drawing conclusions beyond this plain-English summary.
Read the study at New England Journal of Medicine